The Cell Therapy Catapult

Size: px
Start display at page:

Download "The Cell Therapy Catapult"

Transcription

1 The Cell Therapy Catapult Keith Thompson CEO January Catapult is a Technology Strategy Board programme

2 The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing industries for the UK Better exploiting the UK science base Grow and stick 200m+ assigned to TSB for 7 Catapults Hauser Criteria > 10bn pa long term industrial revenue to UK Exploit a strong existing UK science base UK absorptive capacity, to capture and retain value Translational activity to bridge investment gap Learn from other countries with successful Technology Institutes Persistence of funding against a long term perspective and low priority on becoming self-financing

3 The Catapults 3 High Value Manufacturing Offshore renewable Energy Satellite Applications Digital Connected Economy Transport systems Future Cities And

4 Cell Therapy Catapult 4 Significant unmet medical needs World class science base supported by forward looking investments from TSB, MRC; Wellcome Trust, NHS, charities Development and production of cell therapies is complex NHS as large stakeholder for both research and exploitation Early enough for UK to establish a strong market position

5 Mind the (translational funding) gap 5 Little evidence yet that new cell therapies can be developed, licensed and adopted successfully Limited investment from commercial sector Catapult Limited precedents for valuable exits via IPO or acquisition Most large corporates are observing and waiting Operational SME s lack finance and breadth of resources for rapid advance

6 Addressing current industry barriers to commercialisation 6 Key barriers to commercialisation Pertinent issues for cell therapies Regulatory affairs Regulatory pathways still emerging and can be complex Pre-clinical science Investor avoidance of preclinical phase programmes Clinical development Hard to manage demonstration of clinical safety and efficacy Manufacturing and GMP readiness Move from bench/small scale GMP process to large scale manufacture is complex Supply chain management New model of delivery required Investment readiness Difficult for companies and technologies to attract investment

7 Core Purpose 7 Growing a UK cell therapy industry delivering health and wealth

8 Vision 8 The Cell Therapy Catapult vision is for the UK to be a global leader in the development, delivery and commercialisation of cell therapy. Where businesses can start, grow and confidently develop cell therapies, delivering them to patients rapidly, efficiently and effectively.

9 Mission 9 The Cell Therapy Catapult will grow the industry in the UK to substantial and sustainable levels by : Taking products into clinical trial, de-risking them for further investment Providing clinical expertise and access to NHS clinical partners Providing technical expertise and infrastructure to ensure products can be made to GMP and delivered cost effectively Providing regulatory expertise to ensure that products can get to the clinic safely in the shortest time Providing opportunities for collaboration, nationally and globally Providing access to business expertise, grants and investment finance so that commercially viable products are progressed and investable propositions generated

10 Strategic Goals 10 Pipeline Increased cell therapies in UK clinical trial and clinical use Value Investible propositions created leading to cell therapy companies that succeed and stay in the UK Attractiveness Demonstrating that the UK is the place to do this work, with increased inward investment Goals Build a 10bn industry

11 Cell Therapy Catapult Outputs 11 Investible therapies (Rounded Phase 2 data package) Industry assisted over barriers Novel technologies licenced to cell therapy companies Contract research which enhances capability of the industry Standards, quality systems, guidance & co-ordinated framework Skilled, trained and experienced professionals

12 Suitability Projects 12 Proof of Principle 4 people, 12 Months, 0.5m, 2-6 ongoing Scientific, clinical, regulatory, commercial Suitability 0.5 People 3 Months 20k 36 pa Non-clinical 6 people, 24 Months, 2.2m, 2-6 ongoing Safety, toxicology, GMP proving, assays Clinical 5 People, 36 Months, 4.6m, 4-8 ongoing Safety and efficacy, investible data Platform 3 People, 12 Months, 0.5m, 1-3 ongoing Generic issues and large collaborations

13 Project activity 13 Over the Next 5 Years, complete short term suitability and assistance projects proof of principle projects 5-9 non-clinical projects 4-6 clinical projects Participate in the creation of 2-4 significant investible propositions Create an environment that increases clinical trials & clinical activity by %

14 14 Building The Catapult Catapult is a Technology Strategy Board programme

15 Assets 15 Finance 70m core grant from TSB to March m pa from other grant funders 10m pa from industry contracts We use our assets to accelerate innovation. Catapults do not give grants.

16 Facilities and Teams Facilities 1200 sq m on 12 th floor Capacity for people Adjacent to complementary activities Business Team Business development Health economics Business models Translational Labs Process development Analytical development GMP process proving Clinical Trial and Regulatory Team Regulatory Clinical operations 16

17 Building a Project Portfolio 17 Catapult is a Technology Strategy Board programme

18 Global cell therapy industry: Cell-able targets 18 Established medical practice: e.g. haematopoietic stem cell transplantation Commercial products: Rapidly growing global market Global turnover of $1bn in 2011; rising to $5bn in 2014; driven by diversity of small products (Apligraf, Dermagraft, Provenge made >$100m each in 2011) Therapies in development: Rapidly growing ~ 250 products in clinical development Global pharma involvement: Already Teva, Shire, Sanofi, Pfizer

19 Regulatory agency dialogue on plans at each stage Projects: Successful Path to Commercialisation -start with the end product in mind and deliver an integrated plan 19 Science Efficacy and safety hypothesis and evidence Definition and characterisation of cellular product Clinical Manufacturing Patient population, unmet medical need, differentiation Safety Robust evidence of efficacy Dose and dosing regimen GMP manufacturing process; release; comparability assays Supply logistics Scale-up / scale out; Control of cost Business Pricing and reimbursement plan Defensibility (IP, know-how ) Commercialisation partner

20 Projects and Products 20 UK companies SMEs Big Healthcare Inward investors Trial initiation Manufacturing and distribution Academic pull through Accelerate innovation Create investible propositions

21 Drivers in Portfolio Construction 21 Current UK and international activity Cell platform Technology barrier Disease Market size Market access Tractability and deliverability Early wins

22 Diverse cell therapies in clinical trial in the UK; but few are company sponsored 22 Category Number Comment Roughly equal numbers of autologous and allogeneic Cell therapies currently in clinical trial in the UK* ~25 Range of indications from cardiovascular to oncology Bone marrow derived cells still predominate but rising diversity Cell therapies currently in clinical trial in the UK sponsored by a commercial company 4 Majority of studies are Research Council funded and EU consortia studies *verified studies currently on-going; excludes gene therapy & haematopoietic transplantation

23 Bone marrow derived cells still predominate but T-cells are a rising class amongst greater diversity 23

24 Field is growing beyond the traditional transplant and oncology indications 24

25 Opportunities for the Catapult 25 (i) significant potential to grow the clinical translation of therapies originating in the UK and to attract inward investment for clinical development (ii) significant potential to grow the number of UK based cell therapy companies (iii) in order to accelerate towards more approved therapies in this space, more larger Phase 2 studies are required, statistically designed and powered to demonstrate efficacy Cell Therapy Catapult Confidential

26 Identifying projects Catapult widely understood The door is open to all, at all times Screen database against our criteria Initial engagement : suitability project Selected projects progress Board decision against published criteria Portfolio and rationale shown on website

27 Communication Channels Pre-clinical and clinical databases Technology transfer offices Direct contact Intermediaries Grant Funders Industry Groups Charities Investors

28 Gateway Questions

29 Project D: Investigate Further

30 Project E: Return to tracking

31 A

32 B

33 C

34

35

36 Building the Portfolio 36 hesc ips MSC Immune Cell Other Somatic Blood Bone and cartilage Cardiovascular Dermatology/wound healing Diabetes Gastroenterology Immunology Liver Metabolic Neurological Oncology Ophthalmology Respiratory Manufacturability Other

37 Building the Portfolio hesc ips MSC Immune Cell Other Somatic Blood Bone and cartilage Cardiovascular Dermatology/wound healing Diabetes Gastroenterology Immunology Liver Metabolic Neurological Oncology Ophthalmology Respiratory Manufacturability Other 37

38 What does success look like? 38 Catapult is a Technology Strategy Board programme

39 Success for the Cell Therapy Catapult means.. 39 Leadership in building an emerging industry, addressing barriers to commercial investment Increased numbers of cell therapies in UK trials and clinical use Investible propositions creating successful UK companies Demonstrating that the UK is the place to do this work Being a leader in building a 10bn industry

40 Industry Researchers Cell Therapy Catapult NHS Investment Catapult is a Technology Strategy Board programme

41 Commercial Development Plan (start with the end in mind) 41 Start Tasks Product Population Need Commercial Development Plan Innovation Quality Data Substance Process Regulation Information Identity Quantity Diagnostic Patient Clinician Payer Seller

42 Investors in Cell Therapy in the UK (Examples of actual investment or declared interest) 42 Govt. Support Commercial Development Plan Medical Charities Financial Investment Corporate Venturing

43 Working models 43 Nature of project Paid for by: Carried out by: Catapult owned Contracted Development Industry Collaboration Catapult Catapult Catapult Client Grant or Catapult and partner Catapult Client Catapult and partner Ownership of outputs Outputs shared

44 Collaboration 1+1 = 3 Partner Project Input Funding Ratio Client knowledge + Catapult capabilities = Better outcome Up to 80% Technology Strategy Board funding available for collaboration with SME TSB Grant SME 1m 60% 0.6m Catapult 1m 100% 1.0m Total 2m 1.6m 80%

45 Intellectual Property Ownership 45 Basic Principles: Catapult model does not rely upon income from IP Background IP stays with owner Arising IP shared in commercial transaction In proportion to inputs Example: 2m collaboration Urgent new manufacturing process 50/50 Catapult and partner Partner: exclusive rights with their product and business Catapult: rights outside partners business

46 Industry Researchers Cell Therapy Catapult NHS Investment Catapult is a Technology Strategy Board programme

The Cell Therapy Catapult UK Clinical Trials Database

The Cell Therapy Catapult UK Clinical Trials Database May 2015 The UK Clinical Trials Database covers cell therapy clinical trial activity that the Cell Therapy Catapult believes to be ongoing in the UK as of May 2015. It supersedes the database of April

More information

The Cell Therapy Catapult: Achievements and direction of travel

The Cell Therapy Catapult: Achievements and direction of travel The Cell Therapy Catapult: Achievements and direction of travel Professor Johan Hyllner, Chief Scientific Officer Cell Therapy Catapult Catapult is an Innovate UK programme. The Catapults The Catapults

More information

An Introduction to Valuations

An Introduction to Valuations An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your

More information

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare

More information

Project Management. Dissemination and Exploitation Services in Horizon 2020

Project Management. Dissemination and Exploitation Services in Horizon 2020 Project Management Dissemination and Exploitation Services in Horizon 2020 Ontwerp: Studio Edwin de Boer 2 Project Management Dissemination and Exploitation Services in Horizon 2020 ttopstart - Project

More information

From IMI to IMI2. Hugh Laverty PROTECT London

From IMI to IMI2. Hugh Laverty PROTECT London From IMI to IMI2 Hugh Laverty 20.02.2015 PROTECT London Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in Life Science aiming to: Make drug

More information

Large-scale Cell and Gene Therapy Catapult manufacturing facility for current

Large-scale Cell and Gene Therapy Catapult manufacturing facility for current Large-scale Cell and Gene Therapy Catapult manufacturing facility for current and future multiproduct processes October 2016 The Catapults Part of a world-leading network of technology and innovation centres

More information

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

Job Opportunities at the Cell Therapy Catapult

Job Opportunities at the Cell Therapy Catapult Job Opportunities at the Cell Therapy Catapult The Cell Therapy Catapult is a centre of excellence for regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery

More information

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration? ABPI S RESPONSE TO THE BUSINESS, INNOVATION AND SKILLS SELECT COMMITTEE INQUIRY INTO THE STRENGTHS AND WEAKNESSES OF BUSINESS-UNIVERSITY COLLABORATION IN THE UK AND THE UK S PERFORMANCE AGAINST INTERNATIONAL

More information

TERUMO Corporation Business Strategy Conference

TERUMO Corporation Business Strategy Conference TERUMO Corporation Business Strategy Conference THERAPEUTIC SYSTEMS & CELL PROCESSING MARK FLOWER GLOBAL MARKETING December 5, 2011 Regenerative Medicine, Cell Therapy, & Cell Processing Regenerative Medicine

More information

Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development and Use

Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development and Use Advancing Healthcare Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development and Use Jonathan S Leff March 13, 2015 Available Metrics Point to Long-Term Decline

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

Mapping the UK Precision Medicine Landscape

Mapping the UK Precision Medicine Landscape Mapping the UK Precision Medicine Landscape What is precision medicine? Precision medicine refines our understanding of disease prediction and risk, onset and progression in patients, informing better

More information

World-leading expertise in Gene and Cell Therapy

World-leading expertise in Gene and Cell Therapy Worldleading expertise in Gene and Cell Therapy Jefferies Healthcare Conference New York, June 2015 Disclaimer The information contained in this presentation is being supplied and communicated to you on

More information

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH Lucia Faccio, Direttore Sviluppo Ricerca Fondazione Telethon Why should academia transfer

More information

Impact & Innovation in H2020 IP Management & Exploitation

Impact & Innovation in H2020 IP Management & Exploitation Impact & Innovation in H2020 IP Management & Exploitation Jörg Scherer Tallinn 04 March 2015 Get your ticket to innovation. Author: expert Dr. Eugene Sweeney 36 years experience of commercialising IP/research

More information

Guide to submitting your small molecule or therapeutic antibody target

Guide to submitting your small molecule or therapeutic antibody target Guide to submitting your small molecule or therapeutic antibody target Background on MRC Technology Understanding the application review process What MRC Technology looks for in a therapeutic antibody

More information

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Dr. Iiro Eerola Scientific Project Officer Unit for Personalised Medicine Directorate F Health DG Research and European Commission iiro.eerola@ec.europa.eu

More information

The Satellite Applications Catapult: Opportunities for Innovation and Growth. Sarah Johnson, Knowledge Exchange Fellow February 2015

The Satellite Applications Catapult: Opportunities for Innovation and Growth. Sarah Johnson, Knowledge Exchange Fellow February 2015 The Satellite Applications Catapult: Opportunities for Innovation and Growth Sarah Johnson, Knowledge Exchange Fellow February 2015 Catapults: Closing the gap between concept and commercialisation The

More information

Improving Quality in Cellular Therapy with FACT Accreditation. The Foundation for the Accreditation of Cellular Therapy

Improving Quality in Cellular Therapy with FACT Accreditation. The Foundation for the Accreditation of Cellular Therapy Improving Quality in Cellular Therapy with FACT Accreditation The Foundation for the Accreditation of Cellular Therapy 1 Goals and Services of FACT Promote quality patient care and laboratory practice

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information

Investing in Incubation A View from Stevenage Bioscience Catalyst (SBC)

Investing in Incubation A View from Stevenage Bioscience Catalyst (SBC) Investing in Incubation A View from Stevenage Bioscience Catalyst (SBC) Miranda Knaggs, Business Manager You re smart. We care. Join a community making a difference... Building a world class Open Innovation

More information

Jeremy Pearson Cardiovascular Division

Jeremy Pearson Cardiovascular Division Intellectual property exploitation and the successful translation of research Jeremy Pearson Cardiovascular Division Defining and protecting Intellectual Property Deciding on the best way forward Apparent

More information

Regulatory Strategy 101

Regulatory Strategy 101 Regulatory Strategy 101 By Meredith Brown-Tuttle, RAC What is regulatory strategy? As a regulatory associate you hear the word strategy bandied about without any real definition. You know that is what

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

Diagnostic and Medical Device Capabilities Boston Strategic Partners, Inc.

Diagnostic and Medical Device Capabilities Boston Strategic Partners, Inc. Diagnostic and Medical Device Capabilities Boston Strategic Partners is uniquely qualified to work with diagnostic and medical device companies on a variety of engagements Broad experiences with the diagnostic

More information

Understanding the European GMO legislation for gene therapy products in clinical trials

Understanding the European GMO legislation for gene therapy products in clinical trials Understanding the European GMO legislation for gene therapy products in clinical trials Jacqueline Barry Director of Regulatory Affairs Jacqueline.barry@ct.catapult.org.uk Summary Cell & Gene Therapy Catapult

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Regulatory strategies for small companies /SMEs

Regulatory strategies for small companies /SMEs TOPRA Module 1 Strategic planning in RA Regulatory strategies for small companies /SMEs A presentation by Ineke Jonker-Hoogerkamp, Director Regulatory Affairs Neurology, Genzyme Europe BV Learning Outcomes

More information

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Martin LeBlanc, President and CEO, Caprion The 2014 ISPIM Americas Innovation Forum October 6, 2014 1 CHALLENGES FOR

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Stem cells now and in the future: regulation in Australia

Stem cells now and in the future: regulation in Australia John Skerritt National Manager Therapeutic Goods Administration ARCS Scientific Congress 2015 5 May 2015 n biologicals regulatory scheme introduced May 2011 (fully in place by 2014) to: Sets standards

More information

Russell Group response to Science and Technology Committee s inquiry on Bridging the valley of death: improving the commercialisation of research

Russell Group response to Science and Technology Committee s inquiry on Bridging the valley of death: improving the commercialisation of research Russell Group response to Science and Technology Committee s inquiry on Bridging the valley of death: improving the commercialisation of research Summary The Russell Group is pleased to contribute evidence

More information

Hand in Hand with SingHealth Foundation

Hand in Hand with SingHealth Foundation Hand in Hand with SingHealth Foundation SINGHEALTH FOUNDATION is a not-for-profit organisation committed to actively raising funds to support healthcare programmes in its four core areas of Cord Blood

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating

More information

Best research for best practice: policy and practice in clinical research nursing. RCN Research Society Supported by Nurse Researcher

Best research for best practice: policy and practice in clinical research nursing. RCN Research Society Supported by Nurse Researcher Best research for best practice: policy and practice in clinical research nursing RCN Research Society Supported by Nurse Researcher Understand new research infrastructures and opportunities within the

More information

Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC

Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC ISCT Conference, New Zealand, April 2013 April 1 st 2013 NIBSC will become part of the Medicines and

More information

NHS Tayside Strategy for Internationalising Healthcare Delivery

NHS Tayside Strategy for Internationalising Healthcare Delivery NHS Tayside Strategy for Internationalising Healthcare Delivery This strategy document is informed by Healthcare UK publication entitled Enhancing the NHS through International engagement, July 2015 1

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Research Design Service London

Research Design Service London Research Design Service London Enabling Better Research Peter Lovell Programme Manager 27 th October 2011 Overview of presentation An introduction to the NIHR Research Design Service (RDS) Outline of the

More information

BEST PRACTICES RESEARCH

BEST PRACTICES RESEARCH 2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost

More information

Business Presentations and Elevator Pitches

Business Presentations and Elevator Pitches Business Presentations and Elevator Pitches Ed Kania Anesthesiology Conference on Innovation and Entrepreneurship January 18, 2014 ekania@flagshipventures.com Extraordinary People Inspired Ideas Unsolved

More information

15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com. April 17, 2015.

15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com. April 17, 2015. 15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com April 17, 2015 Dear Shareholder, We are experiencing exciting times at HemaCare. Over the course of

More information

Current Topics in the Development and Regulatory Approval of Cancer Therapies

Current Topics in the Development and Regulatory Approval of Cancer Therapies Current Topics in the Development and Regulatory Approval of Cancer Therapies Michelle Ponpipom Associate Director Worldwide Regulatory Affairs Merck & Co., Inc. Oncology Drug Development: Dynamic & Evolving

More information

DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER

DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER Drug Development Office 100 DRUG DEVELOPMENT AND OPERATIONAL STAFF NEW AGENTS IN CLINICAL

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

CLINICAL RESEARCH NETWORK

CLINICAL RESEARCH NETWORK CLINICAL RESEARCH NETWORK Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the

More information

Let the Potential of Your Business Emerge. Paragon Solutions Inc. Proprietary

Let the Potential of Your Business Emerge. Paragon Solutions Inc. Proprietary Let the Potential of Your Business Emerge About Paragon Solutions Paragon provides a full spectrum of consulting services, from advisory through solution design and implementation, for tighter alignment

More information

Your bits will be ready Tuesday - Building a UK Manufacturing Industry in Regenera>ve Medicine

Your bits will be ready Tuesday - Building a UK Manufacturing Industry in Regenera>ve Medicine Your bits will be ready Tuesday - Building a UK Manufacturing Industry in Regenera>ve Medicine Richard Archer (richard@twobc.co.uk) 10th Anniversary High Value Manufacturing Conference 14 November 2012

More information

Pharmacology skills for drug discovery. Why is pharmacology important?

Pharmacology skills for drug discovery. Why is pharmacology important? skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

More information

RFA-OD-14-005: NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD

RFA-OD-14-005: NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD RFA-OD-14-005: NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD Questions Please enter your questions into the webinar chat console If we do not address your question

More information

Elements for optimising Orphan drug development industry perspective

Elements for optimising Orphan drug development industry perspective Elements for optimising Orphan drug development industry perspective IRDiRC Conference, Dublin, 17 April 2013 Wills Hughes-Wilson, Vice President External Affairs, Chief Patient Access Officer, Sobi With

More information

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April 2013 1 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics

More information

Moving an HIV Vaccine from Lab to Clinic: The Importance of Industry Engagement

Moving an HIV Vaccine from Lab to Clinic: The Importance of Industry Engagement Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) Annual Meeting 2013: Moving an HIV Vaccine from Lab to Clinic: The Importance of Industry Engagement Executive

More information

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with

More information

Technology & the Creative Industries in the UK

Technology & the Creative Industries in the UK Technology & the Creative Industries in the UK Rapid commercialising in the UK Tony Hughes, Budapest 2013 UK Market UK s ICT/Consumer Electronics sector is Europe s largest Spend per head is the highest

More information

China Medical Equipment Market Analysis and Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015 Brochure More information from http://www.researchandmarkets.com/reports/1080808/ China Medical Equipment Market Analysis and Forecasts to 2015 Description: China Medical Equipment Market Analysis and

More information

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES HEALTHCARE BIOTECHNOLOGY In Spain the development of ageing medicine presents an excellent business opportunity because the population

More information

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society

More information

A vaccine for rheumatoid arthritis

A vaccine for rheumatoid arthritis A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright

More information

General Legal Service Provider Information Form

General Legal Service Provider Information Form General Legal Service Provider Information Form General information Name of Organisation LK Shields Solicitors Contact information Head of Organisation: Hugh Garvey (Managing Partner) Name: LK Shields

More information

Connected Health (Priority Area D)

Connected Health (Priority Area D) PRIORITY AREA D: CONNECTED HEALTH ACTION PLAN Connected Health (Priority Area D) Context Connected health and independent living technologies are technologies that facilitate remote delivery of healthcare

More information

Research is everybody s business

Research is everybody s business Research and Development Strategy (DRAFT) 2013-2018 Research is everybody s business 1 Information Reader Box to be inserted for documents six pages and over. (To be inserted in final version, after consultation

More information

Governments implement PPP programmes in the healthcare sector for one or more of a number of reasons:

Governments implement PPP programmes in the healthcare sector for one or more of a number of reasons: UNECE Healthcare PPP Project Team Project Brief Introduction This is a very active time globally for the healthcare sector as demand for services continues to grow exponentially, driven by rising life

More information

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine Presented by James Clagett, PhD., Chief Science Officer - The Best Keep Secret in Regenerative Medicine Corporate Headquarters Virginia Beach, VA Who is? helps save lives and restore health for thousands

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

DZIF-Product Development Unit (PDU)

DZIF-Product Development Unit (PDU) November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &

More information

FDA and Rare Diseases. Anne Pariser, M.D. Office of New Drugs Center for Drug Evaluation and Research FDA September 11, 2013

FDA and Rare Diseases. Anne Pariser, M.D. Office of New Drugs Center for Drug Evaluation and Research FDA September 11, 2013 FDA and Rare Diseases Anne Pariser, M.D. Office of New Drugs Center for Drug Evaluation and Research FDA September 11, 2013 Common Ground Effective, safe, quality treatments for patients with rare diseases

More information

The National Centre for Biomedical Engineering Science

The National Centre for Biomedical Engineering Science The How this Integrated Technology Platform has impacted the development of R&D Clusters in Galway Jacinta Thornton, PhD Executive Manager, NCBES National Centre for Biomedical Engineering g Science Mission

More information

House of Lords Select Committee on Science and Technology: Regenerative Medicine

House of Lords Select Committee on Science and Technology: Regenerative Medicine House of Lords Select Committee on Science and Technology: Response by the Wellcome Trust Key Points The UK needs to maintain support for basic research in all avenues of regenerative medicine research,

More information

Stem Cells Market Trends based on Primary Industry Analysis

Stem Cells Market Trends based on Primary Industry Analysis GENReports: Market & Tech Analysis Stem Cells Market Trends based on Primary Industry Analysis > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us > Gary Oosta,

More information

Tech Launch Arizona. Start-up Guide For New Companies Licensing Technologies Invented at the University of Arizona

Tech Launch Arizona. Start-up Guide For New Companies Licensing Technologies Invented at the University of Arizona Tech Launch Arizona Start-up Guide For New Companies Licensing Technologies Invented at the University of Arizona Contents The Idea-to-Impact Continuum... 1 The TLA Start-up Pathway... 3 1. Investigator:

More information

MRC Technology Centre for Therapeutics Discovery

MRC Technology Centre for Therapeutics Discovery MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Early access in practice

Early access in practice Early access in practice On 3 November 2014 Steve Bates, Chief Executive Officer of the BioIndustry Association (BIA) chaired a panel at BIO-Europe in Frankfurt, Germany entitled, Mind the GAP? Meeting

More information

Liberating the NHS regulating healthcare providers consultation on proposals

Liberating the NHS regulating healthcare providers consultation on proposals Liberating the NHS regulating healthcare providers consultation on proposals This document is the response from Association of British Healthcare Industries (ABHI) to the consultation above. ABHI has responded

More information

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any

More information

BioPharma Analytics Informing every move

BioPharma Analytics Informing every move Specialty Solutions Insight Decisions Providers Payors Direction Patients BioPharma Analytics Informing every move Achieve market success faster with evidence-based market intelligence Cardinal Health

More information

GE s Technology and Services

GE s Technology and Services s Technology and Services Analyst Meeting May 4, 2006 Healthcare Healthcare Overview Vishal Wanchoo President & CEO, Healthcare IT 2 / Title or job number Healthcare business model Differentiate with technology

More information

Abbott Nutrition. Attractive Profile and Compelling Growth Opportunities

Abbott Nutrition. Attractive Profile and Compelling Growth Opportunities Attractive Profile and Compelling Growth Opportunities Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation

More information

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. STEM CELL FACTS The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. WHAT ARE STEM CELLS? Stem cells are the foundation cells for

More information

We set things in motion and keep them moving. Metronomia Clinical Research Services

We set things in motion and keep them moving. Metronomia Clinical Research Services We set things in motion and keep them moving Metronomia Clinical Research Services Our customers love the fact that we keep up with their individual tempos. Dorothea Wessiepe, Director Biostatistics Metronomia:

More information

Global Alzheimer s Platform. Luc Truyen, ltruyen8@its.jnj.com George Vradenburg, vradenburg@aol.com Debra Lappin, debra.lappin@faegrebd.

Global Alzheimer s Platform. Luc Truyen, ltruyen8@its.jnj.com George Vradenburg, vradenburg@aol.com Debra Lappin, debra.lappin@faegrebd. Global Alzheimer s Platform 2015 Luc Truyen, ltruyen8@its.jnj.com George Vradenburg, vradenburg@aol.com Debra Lappin, debra.lappin@faegrebd.com 1 Presentation 1. Today s Reality 2. Global Momentum 3. GAP

More information

Cellular Therapy and Cord Blood 2013 Market Report

Cellular Therapy and Cord Blood 2013 Market Report Brochure More information from http://www.researchandmarkets.com/reports/2393891/ Cellular Therapy and Cord Blood 2013 Market Report Description: This is the most up-to-date market report focusing on Cellular

More information

Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer

Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

MRC perspectives? Colin Blakemore

MRC perspectives? Colin Blakemore MRC perspectives? Colin Blakemore The past (BC): some achievements in basic research Chemical transmission in the neuromuscular junction and in synapses Nerve impulse propagation and muscle contraction

More information

BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH

BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH Submission in response to the Discussion Paper November 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health

More information

Abbott Diagnostics. Durable Growth Business

Abbott Diagnostics. Durable Growth Business Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act

More information

Northern Ireland: Newly Inspirational in Clinical Research. Professor Bernie Hannigan, Director, HSC R&D Chief Scientific Advisor, DHSSPS NI

Northern Ireland: Newly Inspirational in Clinical Research. Professor Bernie Hannigan, Director, HSC R&D Chief Scientific Advisor, DHSSPS NI Northern Ireland: Newly Inspirational in Clinical Research Professor Bernie Hannigan, Director, HSC R&D Chief Scientific Advisor, DHSSPS NI Where we are What we are: 1.8 million people (3% of UK) 11 Government

More information

The ASGCT invites you to submit your research to the largest scientific conference of its kind!

The ASGCT invites you to submit your research to the largest scientific conference of its kind! American Society of Gene & Cell Therapy A N N U A L M E E T I N G th May 16-19 2 0 1 2 Philadelphia PA USA The ASGCT invites you to submit your research to the largest scientific conference of its kind!

More information